ArticleJournal of cell communication and signaling2025
Geniposide attenuates astrocyte pyroptosis in depression via long non-coding RNA Six3os1-mediated regulation of the miR-511-3p/COL9A3 axis and MAPK/NLRP3 signaling.
Article in Journal of cell communication and signaling, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Geniposide attenuates astrocyte pyroptosis in depression via long non-coding RNA Six3os1-mediated regulation of the miR-511-3p/COL9A3 axis and MAPK/NLRP3 signaling.Journal of cell communication and signaling · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Depression involves multifaceted molecular pathways, with astrocyte pyroptosis emerging as a critical contributor to neuroinflammation. This study reveals that geniposide, a natural compound, alleviates depressive-like behaviors in chronic unpredictable mild stress mice by targeting a long non-coding RNA (lncRNA)-mediated signaling axis. Bioinformatics analysis identified Six3os1 as a key lncRNA sponging miR-511-3p, thereby upregulating COL9A3 and suppressing the MAPK/NLRP3 pathway. Behavioral tests (sucrose preference, tail suspension, and Morris water maze) demonstrated that geniposide (100 mg/kg) reversed CUMS-induced depressive behaviors. Histological and molecular analyses confirmed geniposide's ability to restore hippocampal integrity, reduce astrocyte pyroptosis, and downregulate pyroptosis markers (ASC, cleaved Casp-1, GSDMD-N, and IL-1β). Dual-luciferase and RNA pull-down assays validated the Six3os1/miR-511-3p/COL9A3 interaction, whereas Western blotting showed geniposide inhibited MAPK phosphorylation (p-p38, p-ERK1/2) and NLRP3 activation. Overexpression of Six3os1 or silencing of miR-511-3p mimicked geniposide's effects, whereas COL9A3 knockdown exacerbated pyroptosis. These findings establish a novel ceRNA mechanism wherein geniposide modulates astrocyte survival via Six3os1-dependent regulation of miR-511-3p and MAPK/NLRP3 signaling, offering therapeutic insights for depression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.